Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation

W. Kreis, Frederick R Ahmann, V. C. Jordan, H. De Haan, M. Scott

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

In patients with histologically confirmed prostate cancer, oestrogen priming with diethylstilboestrol (DES) (3 mg/day) for 4 weeks prior to the first injection of the LHRH agonist Zoladex (3.6 mg depot form) prevented any rise in the serum testosterone concentration. In contrast, in the groups pre-treated with DES, the first, but not subsequent, injections with Zoladex were associated with a marked surge in luteinising hormone. Treatment with DES beyond the time of the administration of Zoladex did not provide further endocrinological advantage. Oestrogen priming for 1 month prior to treatment with Zoladex may prevent an exacerbation of signs and symptoms of prostate cancer.

Original languageEnglish (US)
Pages (from-to)352-354
Number of pages3
JournalBritish Journal of Urology
Volume62
Issue number4
Publication statusPublished - 1988

    Fingerprint

ASJC Scopus subject areas

  • Urology

Cite this